Status: New
| Name & address of the Laboratory/Organization | CSIR-Institute of Himalayan Bioresource Technology (IHBT) | |
| Website address | www.ihbt.res.in | |
| Affiliated to which Department/Ministry | Council of Scientific and Industrial Research (CSIR) | |
| CSR Registration Number | CSR00017422 | |
| Registration under 12A | ||
| Registration under 80G | ||
| Name of the CSR Nodal | Dr. Sukhjinder Singh | |
| Contact information of CSR Nodal | 9418143470, sukhjinder@ihbt.res.in | |
| Principal Investigator | Dr. Narendra Vijay Tirpude , narendra@ihbt.res.in | |
| Co- Principal Investigator (Co-PI) | Dr. Ashish Warghat , ashishwarghat@ihbt.res.in | |
| Objective on the basis of need | Enrichment of active metabolite content (salidrosides and rosavins) in Rhodiola imbricata cell culture and metabolite fingerprinting for quality. Invitro assessment of enriched metabolite preparations on A549 / isolated alveolar or raw 264.7 macrophages for cytocompatibility and efficacy. In-vivo validation of active ingredient combinations and formulations on high fat diet - ovalbumin (ova) induced obesity induced asthma model. |
| Executive summary of the proposed project (In 250 words) | Asthma morbidity, impaired asthma-related quality of life, and sudden onset of asthma are all known risks associated with obesity. Approximately 300 million people globally suffer from asthma, and by 2025, an additional 100 million people are expected to be impacted. The search for alternatives that are both nontoxic and potentially beneficial is urgent. Therefore, preclinical studies to investigate the efficacy of enriched salidrosides and rosavins formulations for obesity asthma. Novelty The proposal is targeted for validating efficacy of plant based natural bioactives (salidrosides and rosavins) already enriched in house by cell suspension culture system. The present proposal also provides a plethora of opportunities for scale-up of metabolite production from endangered medicinal plants without uprooting plants. There is translational opportunity to clinical phase and market potential for increased demand for natural therapies. Objectives Enrichment of active metabolite content (salidrosides and rosavins) in Rhodiola imbricata cell culture and metabolite fingerprinting for quality In-vitro assessment of enriched metabolite preparations on A549 / isolated alveolar or raw 264.7 macrophages for cytocompatibility and efficacy In-vivo validation of active ingredient combinations and formulations on high-fat diet - ovalbumin (ova) induced obesity induced asthma model |
| Technology Readiness Level (If not a new project but an advancement of existing know how) | TRL 1 |
| Outomes or Deliverables | Product formulation using enriched of active metabolite content (salidrosides and rosavins) • C57BL/6J mice model of allergic asthma linked to obesity Outcome Sustainable alternative production of secondary metabolites (i.e. Salidrosides and Rosavins) Safety assessment and bioactivity guided screening of metabolite fractions to cater the entire spectrum of audiences including Nutrition and Health care industry. |
| Project aligned with which most relevant UN SDGs | Goal 3 - Good Health & Well-Being |
| Duration (In years) | 3 years |
| Expected Impact | Product formulation using enriched of active metabolite content (salidrosides and rosavins) • C57BL/6J mice model of allergic asthma linked to obesity Outcome Sustainable alternative production of secondary metabolites (i.e. Salidrosides and Rosavins) Safety assessment and bioactivity guided screening of metabolite fractions to cater the entire spectrum of audiences including Nutrition and Health care industry. |
| Implementation model (self- implemented/ outsourced partnership) | self- implemented/ outsourced partnership |
| Total Budget (Recurring +Non-Recurring Expenses) | 81,12,488.72 |